Compare Consolidated Edison, Inc. (ED) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Sana Biotechnology Inc — how do they compare? Consolidated Edison, Inc. trades at $106.99 (market cap $39.76B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Consolidated Edison, Inc. is far larger — about 35.2× Sana Biotechnology Inc's market cap, and Consolidated Edison, Inc. pays a 3.27% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ED | SANA | |
|---|---|---|
Market Cap | $39.76B | $1.13B |
Sector | Utilities | Health |
52-Week High | $115.46 | $5.92 |
52-Week Low | $95.37 | $2.68 |
Enterprise Value | $66.61B | $1.05B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $107.33, up 0.97% on the day, slightly above the consensus price target of $103.25. The stock shows a mixed technical picture with bearish moving averages but neutral oscillators, while fundamentals are stable with a P/E of 17.68, net income margin of 12.53%, and consistent dividends. Recent Q2 2026 earnings beat estimates with EPS of $0.83 versus $0.756 expected, though Q1 2026 missed expectations.
Outlook is cautious due to analyst sentiment favoring Hold (62.96%) and bearish technical signals, but the utility's regulated operations and mid-8% rate base growth support steady returns. Risks include high debt levels and interest rate sensitivity, while opportunities lie in grid upgrades for AI-driven power demand. The stock offers a defensive profile with a reliable dividend yield.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
